Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon?

Amna Subhan Butt, Fatima Sharif, Shahab Abid

Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon?

Amna Subhan Butt, Fatima Sharif, Shahab Abid, Section of Gastroenterology, Department of Medicine, Aga Khan University Hospital, Karachi 74800, Pakistan

ORCID number: Amna Subhan Butt (0000-0002-7311-4055); Fatima Sharif (0000-0002-3366-9830); Shahab Abid (0000-0003-2530-0378).

Author contributions: All authors have contributed to the study concept, manuscript writing, editing and approval of the final manuscript for publication.

Conflict-of-interest statement: No conflicts of interest to declare.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Abstract

Hepatocellular carcinoma (HCC) is a major cause of morbidity and mortality worldwide. Chronic hepatitis C virus infection (HCV) is the most common cause of HCC in many European countries, Japan and Pakistan. Introduction of the new direct acting antivirals (DAAs) has revolutionized the management of HCV worldwide, with high rates of sustained virologic response in patients who could not have tolerated the previous interferon based treatments. However, recently there have been reports raising caution about the long term effects of DAAs, particularly a possible increased risk of HCC. Therefore this review explores the current molecular studies as well as clinical data that investigate the impact of DAAs on occurrence and recurrence of HCC.

Key words: Hepatocellular carcinoma; Direct acting antivirals; Hepatitis C

© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Our aim is to consolidate the existing literature as well as to identify whether there is a particular subset of the population in which this phenomenon was witnessed. The ground-breaking discovery of the new group of direct acting antiviral agents (DAAs) had led to a paradigm shift in the management of chronic hepatitis C (CHC). Wide variations have been observed in the studies assessing the long-term role of DAA based therapy on occurrence and recurrence of HCC. There is a need to differentiate weather the reported higher occurrence and recurrence rates are due to DAA or host and disease related factors and to identify subset of individuals particularly at risk. Also, future investigations should be directed towards
assessing the long-term effects of DAAs on group of patients that have not been studied thus far. Some important Centers in Europe and United States have been delaying antiviral treatment for 6 mo or more after the recent treatment for HCC. Hence, until more robust data is available, clinical practices should continue as per current guidelines in those patient groups who can benefit from DAA therapy with close surveillance of patients with advance fibrosis.

Butt AS, Sharif F, Abid S. Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon? World J Hepatol 2018; 10(2): 267-276 Available from: URL: http://www.wjgnet.com/1948-5182/full/v10/i2/267.htm DOI: http://dx.doi.org/10.4254/wjh.v10.i2.267

INTRODUCTION

The ground breaking discovery of the new group of direct acting antiviral agents (DAAs) had led to a paradigm shift in the management of chronic hepatitis C (CHC) which is the most common cause of hepatocellular carcinoma (HCC) in Japan, Pakistan, United States and many European countries[1,2]. With annual incidence of HCC ranging from 1% to 7% in patients with HCV related cirrhosis, (HCC) is a leading cause of morbidity and the second most common cause of cancer related deaths worldwide[3,4]. Besides contribution of several host and viral factors in the pathogenesis of disease progression, achieving sustained virologic response (SVR) has been found as the single most important factor in reducing HCV associated HCC incidence[5].

The novel DAAs not only provided a potent, oral alternative to injectable interferons, but also had a shorter duration of treatment, better efficacy with over 90% achievement of SVR and a more favorable side effect profile[6]. However, since 2016, concerns were raised regarding the effect of DAAs on progression to HCC[7]. In addition, their long-term benefits including impact on HCC have been questioned in the context of specific populations and subgroups which were not included in the landmark trials investigating DAA based therapy[8].

Therefore, this review aims to explore existing molecular studies as well as clinical observations in order to determine whether there is an association between the use of DAAs and the occurrence or recurrence of HCC among patients with HCV related liver disease. We also aim to evaluate whether there is a subset of the population in which this phenomenon has been observed.

DAA AND CARCINOGENESIS: BIOLOGICALLY PLAUSIBLE OR NOT?

The carcinogenesis of HCC is a chronic process with several steps that may serve as potential targets for drug therapy. Unlike the hepatitis B virus, HCV is an RNA virus which is unable to integrate into the host genome and thus it is unlikely to have direct carcinogenic activity[9]. While the mechanism of carcinogenesis due to HCV is not completely understood, observations from transgenic mice models suggest that liver cancer occurs because of rapid hepatocyte turnover, dysregulation of apoptosis and generation of reactive oxygen species, arising in the setting of a chronic inflammatory state induced by HCV[9,10]. This indirect mechanism of cirrhosis driven carcinogenesis is supported by clinical data which shows a greater risk of HCC with chronic HCV infection and worsening liver fibrosis[11].

One of the mechanisms proposed regarding the risk of DAAs towards development of HCC is that DAAs downregulate interferon genes, disrupting the innate immunosurveillance of the body[11]. In the chronic phase of HCV, an estimated 1012 virions are produced per day by infected hepatocytes[11]. These trigger an immune response mediated primarily by natural killer (NK) cells which release cytokines such as interferon (IFN)-γ. IFNs upregulate interferon stimulated genes which have an anti-proliferative response by prolonging all phases of the cell cycle and decreasing viral replication. When HCV infection becomes persistent, NK cells become dysfunctional due to continuous antigenic stimulation by the high load of virions, resulting in impaired production of IFNs[12]. In mice models, it was observed that decreased levels of IFN-γ independently control tumorigenesis[13]. Thus the downregulation of these genes in IFN free therapy could contribute to development of HCC.

Analysis of the peripheral blood mononuclear cells (PBMCs) of CHC patients treated with DAAs has shown that in comparison to healthy controls, these patients have attenuated activity of both NK cells and monocytes, reflected by a decreased level of inflammatory cytokines in patients who had achieved rapid virological response (RVR), i.e., undetectable HCV RNA at the end of 4 wk of DAA treatment[14]. Natural Killer cell group 2D (NKG2D) is an activating receptor of immune responses which has been studied in the context of HCV associated HCC. It has been found that in HCV patients treated with IFN free DAA therapy, an on treatment decrease in the expression of NKG2D correlated to the early occurrence and recurrence of clinically evident HCC within the 6-mo surveillance period following treatment[15].

With DAA based therapy, HCV RNA becomes undetectable in days to weeks, a much more rapid response than that observed with IFN based regimens. It is hypothesized that rapid eradication of HCV and subsequent abrupt resolution of the chronic inflammatory state disrupts the natural immune response of the body, possibly favoring the proliferation of neoplastic cells[16]. Since clinical studies have shown no difference among different DAA regimens and development of HCC, it is hypothesized that if this effect does exist then it would have to be a class effect of the DAAs[17,18].
Table 1 Possible factors contributing to hepatocellular carcinoma after hepatitis C virus eradication by direct acting antivirals

| Down regulation of IFN genes | Presence of fibrosis | Sudden disruption of chronic inflammatory state | Impaired immune response by NK cells | T cell dysfunction | Decreased microRNA-122 |
|-------------------------------|----------------------|-----------------------------------------------|-------------------------------------|------------------|------------------------|
| IFN: Interferon; NK: Natural killer. |

An experimental study analyzing the soluble inflammatory milieu from plasma cells of cirrhotic HCV patients found that HCV specific CD8+ T cells failed to recover from the baseline after DAA therapy. These cells play a role in HCC surveillance; therefore, their reduced activity in IFN free therapy could potentially affect development of HCC. Furthermore, serum levels of microRNA (miRNA) 122 were found to be reduced in DAA treated HCV patients after achieving SVR. Previous evidence shows that miRNA-122, which is the most abundant miRNA in the liver, functions as a tumor suppressor against HCC. Thus it is hypothesized that decreased miRNA-122 in DAA treated patients could contribute to an increased risk of HCC recurrence.

Table 1 summarizes the possible factors that could lead to HCC in DAA treated HCV patients.

**DAA AND CARCINOGENESIS: REVIEW OF EXISTING EVIDENCE/DATA**

**Studies that observed increased incidence of HCC**

While DAAs represented a major breakthrough in the treatment of CHCs, one of the first reports questioning their long-term role in development of HCC came from Reig et al. in 2016. The authors retrospectively assessed a cohort of 58 patients who had a history of HCC secondary to HCV and had received different regimens of DAA based therapy. After a median follow up of 5.7 mo (range 0.4-14.6 mo), 16 out of their 58 patients (27.6%) showed radiographic evidence of HCC. This study alerted the scientific community regarding the potential risks associated with use of DAAs and the authors called for a large-scale assessment to confirm their findings. However, their method of statistical analysis was questioned by Camma and colleagues who felt that reporting the crude rate of recurrence was a weakness of the study because of the variation in time elapsed from treatment of HCC and starting DAAs (median 11.2 mo, range 1.2-87.7 mo). Cammà et al. used the data presented by Reig et al. to calculate the actuarial probability of HCC recurrence by plotting a Kaplan Meier curve. For their analysis, Cammà et al. used the time of HCC treatment as the initiation point, not the time of initiating DAA treatment as used by the original authors. With this method they found a much lower recurrence rate than that reported in the original study (7% and 13% at 6 and 12 mo respectively).

Reig et al. later went on to present a follow up of their original cohort. In 2017, they reported that not only did they observe a higher recurrence rate of HCC following DAA treatment with a more aggressive pattern of recurrence in terms of tumor staging and subsequent treatment options. Renzulli et al. have also reported a rapid development of HCC following DAA treatment with a more aggressive pattern of microvascular invasion. The median duration between completion of DAA treatment and diagnosis of HCC in their patients was 82 d (range 0-318).

A retrospective study from Italy by Conti et al. reported HCC occurrence and recurrence rates of 3.16% (95%CI: 1.45-5.90) and 28.81% (95%CI: 17.76-42.07) respectively in a cohort of 344 CHC patients treated with different DAA regimens over a follow up of 24 wk. Approximately 69% of this patient population had HCV genotype 1 and 91% had achieved SVR. However, the lack of a control group makes the interpretation of these findings difficult. The authors attempted to account for this limitation by comparing their findings to those of a historic cohort of untreated cirrhotic patients at their center. They found an HCC occurrence rate of 3.2%, which was similar to their current study. Conti et al. have interpreted their results with caution. The authors claim that while DAA treatment of HCV does not seem to reduce the occurrence or recurrence of HCC, antiviral treatment should be started as early as possible to prevent the development of cirrhosis and recommend active surveillance of all cirrhotic patients, during and after DAA therapy.

In Portugal, Cardoso et al. found HCC incidence to be 7.4% within a one year follow up of cirrhotic patients that had achieved SVR after being treated with sofosbuvir and ledipasvir. These de novo HCC patients had been asymptomatic, and were detected on radiological screening. This emphasizes the recommendation of Conti et al. that there should be close monitoring of CHC patients for development of HCC, despite achieving SVR. In a larger study from Belgium, it was found that there was no difference in the early occurrence of HCC among patients treated with DAAs with or without Peg-IFN. However, this study reported HCC recurrence of 15% in patients treated with DAAs alone as compared to 0% in those who received a combination of Peg-IFN and DAAs. This study had a predominantly HCV Genotype 1 population. In these patients the authors also noted that those who developed HCC had a higher baseline risk of HCC which is a potential confounder.

The most recent study on this research question is by Ida et al., published in October 2017. The study population comprised 100 patients from Japan with HCV genotype 1, treated with Daclastavir and Asunaprevir, who were followed for 15 mo. In this group, there were 5 new cases and 12 recurrences of HCC. The authors
have hypothesized that the high rate of HCC seen in this study could be related to a history of HCC, as these patients already had advanced fibrosis which is known to be implicated in the process of hepatocarcinogenesis.

Table 2 summarizes the studies that report an increased incidence of HCC in DAA treated HCV patients.

Studies that did not note any significant effect
In 2016 and 2017 there have been several other similar reports, fueling the debate regarding the role of DAAs in HCC. Two large retrospective cohort studies have been conducted in the United States to investigate this matter; one by Ioannou et al.[33] with a sample size of 62354 and the other by Kanwal et al.[34] with 22500 study participants. Both studies concluded that DAAs are not associated with a significant risk of HCC as compared to IFN based treatment. Ioannou et al.[33] found that DAA induced SVR reduced the risk of HCC by 71%. This effect was similar in groups who had received DAAs alone, DAAs in combination with IFN or IFN alone regimens, thus suggesting that achieving SVR could be the crucial factor for risk reduction of HCC, regardless of the therapeutic agents used.[33]. Kanwal et al.[34] found that while there was a relative risk reduction in HCC, the absolute risk of HCC still persisted in those patients who had DAA induced SVR. In both studies the risk of HCC was greater in cirrhotic patients. Additionally, Kanwal et al.[34] found that diabetes mellitus, alcohol use and a higher Fib-4 Index for assessment of fibrosis were risk factors for occurrence of HCC in patients who had achieved SVR. However, both study populations were restricted to United States veterans and were mostly patients with HCV genotype 1. The specific population included in these studies might limit the generalization of their findings.

The ANRS Collaborative Study Group assessed HCC recurrence rates among 3 French multicenter prospective cohorts who had received DAA based therapy after HCC curative treatment.[35]. Their study included a diverse patient population with cirrhotos, non-cirrhotos and liver transplant recipients. They did not find any evidence that DAAs increases the risk of HCC recurrence. The strength of this study was that analysis of data from 3 distinct patient cohorts yielded fairly consistent results. Secondly, they included patients who had received curative therapy for HCC as opposed to non-curative therapies such as chemoembolization, leading to speculation that some of the earlier studies that had reported a higher recurrence rate might have included patients in whom the initial tumor staging was incorrect or was incompletely treated.[35]. Table 3 summarizes the studies that do not show an increased risk of HCC in DAA treated patients.

Geographical variation of incidence of HCC in DAA treated patients
Many of the studies investigating the link between DAAs and HCC have been from Japan or European countries. Racial differences are known to be implicated in the progression to HCC among HCV infected patients.[52]. In a large cohort of United States veterans with HCV, it was found that Hispanics were at greater risk of developing cirrhosis and HCC. Black race and Hispanic ethnicity have also been identified as independent predictors of treatment failure[53]. Indeed the first report raising caution about the possible association of DAAs with recurrence of HCC in an aggressive form did come from the Spanish cohort followed by Reig et al.[38].

A systematic review and meta-analysis by Waziry et al.[34] found that there was no difference in HCC occurrence and recurrence in CHC patients who received IFN based or DAA based regimens. However, the authors acknowledge that in their analysis they were unable to account for geographical variations. Due to the heterogeneity in the studies included in this meta-analysis, the results should be interpreted with caution. In this meta-analysis most of the IFN based studies were from Japan whereas DAA based studies were from Europe. Hence, due to baseline difference in between two populations it’s hard to draw an accurate conclusion regarding occurrence or recurrence of HCC among DAA and IFN based therapy. Furthermore, they had to exclude several studies which had incomplete data regarding BCLC staging of HCC.

In our literature review, the populations that we have found to be under-represented in terms of the current research question include Indians, Arabs and Africans. Additionally, while the 2 studies with the largest sample size are from the United States, these were limited to veterans only[33,34].

Genotype based variation of HCC in DAA treated patients
HCV genotype is an important consideration when considering progression to HCC. HCV genotype 3 is generally more aggressive and is associated with a higher risk of progression to cirrhosis and HCC[55]. To the best of our knowledge, the studies published so far suggesting a greater risk of HCC with DAA treatment have not identified a particular genotype of HCV that is significantly associated with this disease progression. However, as most of these reports are from Japan or European countries such as France and Italy, therefore the major disease burden studied has been of HCV genotype 1.[35,37]. Table 4 lists the factors predisposing to development of HCC in DAA treated HCV patients.

WAY FORWARD
There is wide variation in the studies assessing the long-term role of DAA based therapy on occurrence and recurrence of HCC, both in terms of the baseline characteristics of study population and the different DAA regimens used. At present, most of the studies have been reported from regions where HCV genotype 1 is the most prevalent one[24,38]. Data is very limited from Asian populations where HCV Genotype 3 is the most common genotype. This is an important consideration as the different genotypes of HCV have a unique
## Table 2: Studies showing an increased incidence of hepatocellular carcinoma in direct acting antivirals treated patients

| Ref.                  | Treatment groups | Country/sample size | Male gender n (%) | Age (yr) | Genotype n (%) | Duration of follow up | Cirrhosis n (%) | History of HCC n (%) | Incidence of HCC | HCC occurrence | HCC recurrence |
|-----------------------|------------------|---------------------|-------------------|----------|----------------|----------------------|----------------|----------------------|------------------|----------------|----------------|
| Reig et al[8]         | All DAA treated  | Spain n = 58        | 40 (69)           | Median 66.3 (45-83) | GI α = 8 (13.8%), G1b = 45 (77.6%), G3 = 2 (3.4%), G4 = 3 (5.2%), G1 = 257 (43.5%), G2 = 40 (11.6%), G3 = 38 (11), G4 = 29 (8.4) | median 5.7 mo | 55 (94.8) | 58 (100) | Not applicable | 16 (27.6%) |
| Conti et al[18]       | All DAA treated  | Italy n = 344       | 207 (60.2)        | Median = 63 (29-85) | G1a = 8 (13.8%), G1b = 45 (77.6%), G3 = 2 (3.4%), G4 = 3 (5.2%), G1 = 257 (43.5%), G2 = 40 (11.6%), G3 = 38 (11), G4 = 29 (8.4) | 24 wk | 59 (17) | 9 of 285 patients | (5.16%, 95% CI: 1.45-5.93) | 17 of 59 patients | (28.81%, 95% CI: 17.76-42.07) |
| Cardoso et al[26]     | All DAA treated  | Portugal n = 54     | > 70%             | Median = 63 (29-85) | G1a = 8 (13.8%), G1b = 45 (77.6%), G3 = 2 (3.4%), G4 = 3 (5.2%) | Median = 32.0 mo (9.4-12.5 mo) | All cirrhotic | 0 (0) | 4 (7.4%) | Not applicable |
| Ida et al[28]         | All DAA treated  | Japan n = 100       | 46 (46%)          | Median 72.5 (68-74 yr) | GI = 100 (100), G1b = 3 (13.8%), G3a = 13 (68.4%), G3b = 2 (10.5), G4a = 1 (5.2) | 15 mo | 26 (26) | 5 (5) | 12 (12) | 3 patients |
| Issachar et al[28]    | All DAA treated  | Israel n = 273      | 208/38 (62)       | Median 55 (49-60 yr) | GI = 100 (100), G1b = 3 (13.8%), G3a = 13 (68.4%), G3b = 2 (10.5), G4a = 1 (5.2) | 15 mo | Median 493 d | All cirrhotic | - | 6 (2.1) |
| Kwong et al[28]       | All DAA treated  | United States n = 48158 | 298/58 (62) | - | - | - | - | Incidence Rate of HCC was 49% higher in the DAA era (IR 6.6/100 person-years [py], 95% CI: 5.6-7.9 vs the IFN era (4.5/100 py, 95% CI: 4.2-4.7; IRR 1.49, 95% CI: 1.24-1.79, P < 0.001) | Not applicable |
| Strazzulla et al[29]  | daclatasvir and  | Italy n = 1 case     | 1 male            | 53 | GI | 24 wk | Decompensated cirrhosis | Treated | Not applicable | - | 1 recurrence |
| Simeprevir for 24     | weeks to reach   | report               |                  |      |    |          |                  |                  |                      |                 |               |
| weeks to reach SVR    |                    |                      |                  |      |    |          |                  |                  |                      |                 |               |
| Bielen et al[31]      | PEG-IFN + DAA = 77 | Belgium n = 567     | PEG IFN + DAA     | 1/77 (1.3%), DAA alone: 41/490 (8.4%) | Early occurrence rate of HCC = 1.7% and 1.1% in patients treated with DAA with and without PEG-IFN, respectively | 6 mo | Metavir fibrosis score F3/F4 included only | PEG IFN + DAA | Early recurrence rate was 0% in patients treated with PEG-IFN+DAA and 15.0% in patients treated with DAA without PEG-IFN |

DAAs: Direct acting antivirals; IFN: Interferon; HCC: Hepatocellular carcinoma.

Butt AS et al. The dilemma of DAA and HCC development
| Ref. | Treatment N /sample size | Country        | Male gender n (%) | Age (yr) | Genotype n (%) | Duration of follow up | Cirrhosis n (%) | History of HCC n (%) | HCC occurrence | HCC recurrence |
|------|-------------------------|----------------|-------------------|----------|----------------|----------------------|----------------|----------------------|----------------|---------------|
| Ioannou et al [33] | IFN only = 3,867 (58%), DAA + IFN = 4,355 (7.2%), DAA only = 21,948 (35%) n = 62,534 | United States | 96.60% | Mean 55.8 ± 7.6 | G1 = 77.4%, G2 = 13.5%, G3 = 8.3%, G4 = 0 | Mean follow-up DAA only group = 1.53 years, DAA+IFN group = 3.6 yr, IFN only group = 9.1 yr | Cirrhosis: 16.8%, decompensated cirrhosis: 4.7% | None | Total 3,271 incident cases. IFN group = 0.81/100 person years, DAA + IFN = 1.06/100 py, DAA only = 1.32/100 py | Not applicable |
| Kanwal et al [34] | All DAA treated n = 22,500 | United States | 96.7% | Mean 61.6 ± 6.1 | G1 = 19,531 (86.6%), G2 = 1,422 (6.3%), G3 = 940 (4.2%), G4 = 6 (0.3%) | Mean follow-up DAA only group = 1.53 years, DAA+IFN group = 3.6 yr, IFN only group = 9.1 yr | Cirrhosis: 16.8%, decompensated cirrhosis: 4.7% | None | Total 3,271 incident cases. IFN group = 0.81/100 person years, DAA + IFN = 1.06/100 py, DAA only = 1.32/100 py | Not applicable |
| ANRS-CO22 HEPTH-ER et al [35] | DAA group = 18,9, no DAA = 78 n=267 | France | 65% | Mean 217,6 ± 14.1 | DAA group = 147 (78%) DAA group = 62 ± 9 yr, no DAAs = 66 ± 10 yr | Median 20.2 mo after DAA initiation and 26.1 mo for untreated patients | All cirrhotic | All treated | Not applicable | DAA group = 24 (12.7%), no DAAs = 16 (20.5%) |
| ANRS-CO12 CIRVIR et al [36] | DAA group = 13, no DAA = 66 n = 79 | France | 65% | Mean 257 (82%) | DAA group = 212 (67.5%) genotype 1 (58.3%), 1b (6.3%), 2a (18.2%), 3 (4.9%), 4 (2.8%) | Median 6, 12 and 18 mo | All cirrhotic | All treated | Not applicable | 7 (2.2%) |
| Nagata et al [37] | IFN-based: 1145. IFN-free DAA group: 752 n = 1897 | Tokyo | 65% | Median 28, 61 ± 8 yr | DAA group = 11 ± 10 yr, no DAAs = 65 ± 9 yr | Median for IFN group: 6.8 (0.2-22.0); IFN free: 1.8 (0.1-7.7) | 5% of IFN group, 11% of IFN free group | IFN group: 18 (2.5%), IFN-free group: 7 (1.1%) | IFN group: 18 (53%), IFN-free group: 22 (29%) |
| Ikeda et al [38] | All DAA treated n = 177 | Japan | 65% | Mean 80 (60.3) | DAA group = 61 (39%); 1a = 22 (22%), 1b = 93 (93%), 2a = 182 (16%), 3 (4.9%), 4 (2.8%) | Median 20.7 mo | All cirrhotic | All treated | Not applicable | 6, 12- and 18-mo HCC recurrence rates were 12%, 26.6% and 29.1%, respectively |
| Zanetto et al [39] | DAA treated= 23, control = 23 n = 46 | Italy | 65% | Mean 90 (49-69) | DAA group = 59 (49-69), controls = 58 (46-70) | Median = DAA group = 10 mo, Control group = 7 mo | All cirrhotic | All treated | Not applicable | 12.5% of DAA-treated patients and 8.3% of control group had HCC recurrence (P = 0.60) |
| Study | Treatment | Country | n | Median Age | Genotype | Time After Therapy | Cirrhosis | Treated | Notes |
|-------|-----------|---------|---|------------|-----------|-------------------|-----------|---------|-------|
| Zavaglia et al [40] | All DAA treated | Italy | 31 | Mean 65 ± 8 | G1a = 4 (13), G1b = 23 (74), G2 = 2 (6.5), G4 = 2 (6.5) | Median 8 mo | All cirrhotic | All treated | Not applicable | 1 (3.2) |
| Ogata et al [41] | All DAA treated | Japan | 1170 | Median 67 (21-48) | All genotype 1 | Median 8 mo | All cirrhotic | None | 22 cases (1.8%) | Not applicable |
| Minami et al [42] | DAA group = 27, IFN group = 38, Controls = 861 | Japan | 20 (64.5) | G1a = 4 (13), G1b = 23 (74), G2 = 2 (6.5), G4 = 2 (6.5) | Genotype 1: DAA = 21 (78), IFN = 29 (76), Controls = 63 (74), Genotype 2: DAA = 6 (22), IFN = 9 (24), Control = 147 (17) | Time from the end of DAA therapy until last visit: 1.3 yr | 1 and 2 yr | All treated | Not applicable | Cumulative recurrence rates at 1 and 2 yr were 21.1% and 29.8%, respectively, in the DAA group, 26.3% and 52.9%, respectively, in the IFN group, and 30.5% and 61.0%, respectively, in the control group |
| Deterding et al [43] | n = 974 | Germany | G1 = 745 (76.2) | Median 42 wk for recurrence | All had advanced cirrhosis | 48 (8%) | 20 (4%) estimated annual incidence of 1.6%, 9 (19%), annual incidence of 7.7% |
| Degasperi et al [44] | n = 565 | Italy | 60% | Mean 65 ± 8 | G1a = 15%, G1b = 49%, G2 = 13%, G3 = 11%, G4 = 12%, G5 = 1% | Median 42 wk for recurrence | All cirrhotic | G1 = 18% (27), G2 = 10% (15), G3 = 5% (7), G4 = 2% (3), G5 = 1% (2) | 9 (19%), annual incidence of 7.7% |
| Bourliere et al [45] | DAA + RBV ± PEG IFN = 21%, IFN free DAA therapy = 79% | n = 1393 | 47 (19-79) yr | G1 = 69% (20), G2 = 10% (3), G3 = 8% (2), G4 = 12% (4), G5 = 1% (2) | Median for PEG-IFN/RBV = 96 (10-196) and DCV/ASV group = 23 (4-78) mo | None | None | 0 (0) | 0 (0) |
| Nagaoki et al [46] | PEG-IFN/ RBV = 244, DCV/ASV = 154 n = 398 | Japan | 47 (19-79) yr | G1 = 69% (20), G2 = 10% (3), G3 = 8% (2), G4 = 12% (4), G5 = 1% (2) | Median for PEG-IFN/RBV = 96 (10-196) and DCV/ASV group = 23 (4-78) mo | None | None | 0 (0) | 0 (0) |
| Cheung et al [47] | All DAA | United Kingdom | 198 (48.8) 171 (42.3) | Median 15 mo | All decompensated cirrhosis | 29 (71.4%) | 17 (5%) | 2 |
| Mettke et al [48] | 158 DAA treated, 184 controls | Germany | Median 440 (91-1008) and 592 (90-1000) d | Median 440 (91-1008) and 592 (90-1000) d | Median 440 (91-1008) and 592 (90-1000) d | Median 440 (91-1008) and 592 (90-1000) d | 6 and 14 patients during follow-up, resulting in an HCC incidence of 2.9 (AVT) and 4.48 (Con) per 100 py, respectively |
| Ji et al [49] | China | 51% | Mean age 51 | G1 = 6 (75%), mixed genotype = 2 (25%) | Median 14 (3-35) mo | 48% cirrhotic | None | 44 (51.5%) | Not applicable |
| Innes et al [50] | Scotland | United States | 7 (87.5%) | Mean age 51 | G1a = 4 (13), G1b = 23 (74), G2 = 2 (6.5), G4 = 2 (6.5) | Median 64 (57-87) years | 48% cirrhotic | None | Not applicable |
| Torres et al [51] | All DAA treated | United States | 7 (87.5%) | Mean age 51 | G1a = 4 (13), G1b = 23 (74), G2 = 2 (6.5), G4 = 2 (6.5) | Median 64 (57-87) years | 48% cirrhotic | None | Not applicable |

DAAs: Direct acting antivirals; IFN: Interferon; HCC: Hepatocellular carcinoma.
response to DAA based therapy and are associated with a unique burden of HCC. Beside male patients, group of individuals with prior history of HCC, cirrhosis and elevated AFP at baseline were found with greater risk of HCC if treated with DAAs. Currently, the phenomenon appears to be a class effect rather than an individual drug effect. Hence, focusing on these HCV patients and measuring the impact of DAAs on progression or development of HCC will help to estimate the more accurate risk. In certain studies higher rates of HCC recurrence was found. There is a need to differentiate whether the reported higher recurrence rate and more aggressive pattern of recurrence are due to DAA or host or disease related factors including presence of fibrosis, gaps in initial tumor staging and receiving non-curative therapies such as chemoembolization. Also, future investigations should be directed towards assessing the long-term effects of DAAs on these populations that have not been studied thus far. In the meantime, a consensus recommendation seen in most of the studies at present is that even after achieving SVR, there should be close surveillance of patients with CHC especially with advance fibrosis and those who received a recent treatment for HCC in order to detect HCC at an early stage. Some important Centers in Europe and United States have been delaying antiviral treatment for 6 mo or more after recent treatment for HCC in these patients. Moreover, until more robust data is available to investigate the role of DAAs in HCV related HCC cases, clinical practice should continue as per current guidelines in those patient groups who can benefit from DAA therapy.

**REFERENCES**

1. Hsu CS, Chao YC, Lin HH, Chen DS, Kao JH. Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular Carcinoma. *Sci Rep* 2015; 5: 9954 [PMID: 25963067 DOI: 10.1038/srep09954]
2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. *Gastroenterology* 2012; 142: 1264-1273 [PMID: 22537432 DOI: 10.1053/j.gastro.2012.11.061]
3. Goossens N, Hoshida Y. Hepatitis C virus-induced hepatocellular carcinoma. *Clin Mol Hepatol* 2015; 21: 105-114 [PMID: 26157746 DOI: 10.3350/cmh.2015.21.2.105]
4. Siegel R, Ma J, Zou Z, Jamal E. Cancer statistics, 2014. *CA Cancer J Clin* 2014; 64: 9-29 [PMID: 24399786 DOI: 10.3322/caac.21208]
5. Moon C, Jung KS, Kim DY, Baatakhruu O, Park JY, Kim BK, Kim SU, Ahn SH, Han KH. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. *Dig Dis Sci* 2015; 60: 573-581 [PMID: 25236421 DOI: 10.1007/s00410-014-3361-6]
6. Cortez KJ. Kottilil S. Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. *Ther Adv Chronic Dis* 2015; 6: 4-14 [PMID: 25553238 DOI: 10.1177/20462231451934]
7. Grandhe S, Frenette CT. Occurrence and Recurrence of Hepatocellular Carcinoma After Successful Direct-Acting Antiviral Therapy for Patients With Chronic Hepatitis C Virus Infection. *Gastroenterol Hepatol* (NY) 2017; 13: 421-425 [PMID: 28867970]
8. Reig M, Marriño Z, Perelló C, Ibarraegiag M, Ribeiro A, Lens S, Díaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X, Bruix J. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. *J Hepatol* 2016; 65: 719-726 [PMID: 27084592 DOI: 10.1016/j.jhep.2016.04.008]
9. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. *Nat Med* 1998; 4: 1065-1067 [PMID: 9734402 DOI: 10.1038/2053]
10. Kamegaya Y, Hiasa Y, Zukerberg L, Fowler N, Blackard JT, Lin W, Choe WH, Schmidt EV, Chung KT. Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. *Hepatology* 2005; 41: 660-667 [PMID: 15723444 DOI: 10.1002/hep.20621]
11. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. *Science* 1998; 282: 103-107 [PMID: 9756471 DOI: 10.1126/science.282.5386.103]
12. Mondelli MU, Varchetta S, Oliverio B. Natural killer cells in viral hepatitis: facts and controversies. *Eur J Clin Invest* 2010; 40: 851-863 [PMID: 20597961 DOI: 10.1111/j.1365-2362.2010.03323.x]
13. Street SE, Cretney E, Smyth MJ. Periforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. *Blood* 2001; 97: 192-197 [PMID: 11133760 DOI: 10.1182/blood.V97.1.192]
14. Ning G, Li YT, Chen YM, Zhang Y, Zeng YF, Lin CS. Dynamic Changes of the Frequency of Classic and Inflammatory Monocytes Subsets and Natural Killer Cells in Chronic Hepatitis C Patients Treated by Direct-Acting Antiviral Agents. *Can J Gastroenterol Hepatol* 2017; 2017: 3612403 [PMID: 28567369 DOI: 10.1155/2017/3612403]
15. Chu PS, Nakamoto T, Taniki N, Ojiro K, Amiya T, Makita Y, Murata H, Yamaguchi A, Shiba S, Miyake R, Katayama T, Moriya K. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. *J Hepatol* 2016; 65: 719-726 [PMID: 27084592 DOI: 10.1016/j.jhep.2016.04.008]
16. Llovet JM, Villanueva A. Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC. *Nat Rev Gastroenterol Hepatol* 2016; 13: 561-562 [PMID: 27580683 DOI: 10.1038/nrgastro.2016.140]
17. Bianco JR, Rivero-Juarez A. The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it? *Expert Rev Anti Infect Ther* 2016; 14: 993-996 [PMID: 27688837 DOI: 10.1080/14787271.2016.1243466]
18. Conti F, Buonfiscio F, Scutieri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzii M, Mazzella G, Veruci G, Andreone P, Brillanti S. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. *J Hepatol* 2016; 65: 727-733 [PMID: 27349488 DOI: 10.1016/j.jhep.2016.06.015]
19. Sekyere SO, Falk C, Areagay A, Schlevoigt B, Deterding K, Manns MP, Vogel A, Wirth T, Cornberg M, Wedemeyer H. GS-003-Interferon-free cure of hepatitis C virus infection.
does alter the soluble inflammatory milieu which could affect hepatocellular carcinoma surveillance by CD8+ T cells in patients with liver cirrhosis. J Hepatol 2017; 66: S2 [DOI: 10.1016/j.jhep.2016.12.026-60]

20 Waring JF, Duggal EO, Abel S, Coakley E, Cohen DE, Davis JW, Podsadecki T, Dutta S. Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effects of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects. J Viral Hepat 2016; 23: 96-104 [PMID: 26436610 DOI: 10.1111/jvhe.12470]

21 Nakao K, Miyaihi H, Ichikawa T. Antitumor function of microRNA-122 against hepatocellular carcinoma. J Gastroenterol 2014; 49: 588-593 [PMID: 24531873 DOI: 10.1007/s00535-014-0922-4]

22 Liu CH, Kao JH. Hepatocellular carcinoma recurrence after interferon-free direct acting antiviral treatment for chronic hepatitis C virus infection: fact or fiction? Transl Cancer Res 2016; 5: S192-195 [DOI: 10.21037/tcr.8773]

23 Cammà C, Cabibbo G, Craxi A. Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing. J Hepatol 2016; 65: 861-862 [PMID: 27255578 DOI: 10.1016/j.jhep.2016.04.033]

24 Reig M, Maríoro Z, Perello C, Ihnarragasti M, Lens S, Díaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL. PS-031- Tumour recurrence after Interferon-free treatment for hepatitis C in patients with previously treated hepatocellular carcinoma discloses a more aggressive pattern and faster tumour growth. J Hepatol 2016; 57: S20 [DOI: 10.1016/S0168-8278(17)30302-1]

25 Renzulli M, Buonfiglioli F, Conti F, Brocchi S, Serio I, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Petta S, Calvaruso V, Cacciola I, Cannavò MR, Kozbial K. Chronic Hepatitis C Virus Infection. Viral Response with Daclatasvir and Asunaprevir in Patients with HCV Cirrhosis. J Hepatol 2017; 67: S192-195 [DOI: 10.21037/8773]

26 Butt AS et al. The dilemma of DAA and HCC development
Butt AS et al. The dilemma of DAA and HCC development

Detering K, Mauss S, Pathil A, Buggisch P, Schott E, Cornberg M, Zimmermann T, Simon KG, Klinker H, Günther R, Pfeiffer-Vornkahl H. PS-096-Long-term follow-up after IFN-free therapy of advanced HCV-associated liver cirrhosis: continued improvement of liver function parameters–Results from the German Hepatitis C-Registry (DHC-R). J Hepatol 2017; 66: S55 [DOI: 10.1016/S0168-8278(17)30372-0]

Degasperi E, D’Ambrosio R, Sangiovanni A, Aghemo A, Soffredini R, De Nicola S, Lunghi G, lampertico P. Low rates of de novo or recurrent hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals (DAAs): a single-center experience. Hepatology 2017; 66: 46A

Bourliere M, Gane EJ, Jacobson I, Gordon SC, Sulkowski MS, D’Ambrosio R, Sangiovanni A, Aghemo A, Subramanian M. Long-Term Follow Up of Patients with Chronic HCV and No or Minimal Fibrosis Shows Low Risk for Liver-Related Morbidity and Mortality After Achieving SVR with DAA-Based Therapy: Results from the Gilead SVR Registry. Hepatology 2017; 66: 518A-519A

Nagaoki Y, Imamura M, Aikata H, Dajio K, Teraoka Y, Honda F, Nakamura Y, Hatouka M, Morio R, Morio K, Kan H, Fujino H, Kobayashi T, Masaki K, Ono A, Nakahara T, Kawaoka T, Tsuge M, Hiramat su A, Kawakami Y, Hay es CN, Miki D, Ochi H, Chayama K. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. PLoS One 2017; 12: e0182710 [PMID: 28797106 DOI: 10.1371/journal.pone.0182710]

Cheung MCM, Walker AJ, Hudson BE, Verma S, McLaughlan J, Mutimer DJ, Brown A, Nelson WTH, MacDonald DC, Agarwal K, Foster GR, Irving WL; HCV Research UK. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016; 65: 741-747 [PMID: 27388925 DOI: 10.1016/j.jhep.2016.06.019]

Mettke F, Schiełowt B, Deterding K, Wranke A, Port K, Manns MP, Vogel A, Cornberg M, Wedemeyer H. THU-081-Interferon-free therapy of chronic hepatitis C does not change the short-term risk for de novo hepatocellular carcinomas in patients with liver cirrhosis. J Hepatol 2017; 66: S210-211

Ji D, Wang C, Shao Q, Li F, Li B, Wu V, Tong A, Wang YD, Chen J, Chen GF, Lau G. No increase in the occurrence rate of hepatocellular carcinoma in Chinese treated by direct-acting antivirals compared to Interferon after eradication of hepatitis c virus: a long-term follow-up. J Hepatol 2017; 66: S23 [DOI: 10.1016/S0168-8278(17)30308-2]

Innes H, Barclay ST, Hayes PC, Fraser A, Dillon JF, Stanley A, Bathgate A, McDonald S, Goldberg D, Valerio H, Fox R. PS-035-Among Cirrhotic Patients with a Hepatitis C Sustained Viral Response, the Risk of De-novo Hepatocellular Carcinoma Relates to Baseline Factors and Not the Use of Direct Acting Antivirals: Results from a Nationwide Cohort. J Hepatol 2017; 66: S22-3 [DOI: 10.1016/S0168-8278(17)30306-9]

Torres HA, Vautheny JN, Economides MP, Mahale P, Kaseh A. Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. J Hepatol 2016; 65: 862-864 [PMID: 27255582 DOI: 10.1016/j.jhep.2016.05.034]

El-Serag HB, Kramer J, Duan Z, Kanw al F. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol 2014; 109: 1427-1435 [PMID: 25070058 DOI: 10.1038/ajg.2014.214]

Su F, Green PK, Berry K, Ioannou GN. The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology 2017; 65: 426-438 [PMID: 27775854 DOI: 10.1002/hep.28901]

Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, George J, Dore GJ. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol 2017; 67: 1204-1212 [PMID: 28802876 DOI: 10.1016/j.jhep.2017.07.025]

Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular carcinoma in a national sample of U.S. Veterans with HCV. Hepatology 2014; 60: 98-105 [PMID: 24615981 DOI: 10.1002/hep.27095]

Ampuero J, Romero-Gómez M, Reddy KR. Review article: HCV genotype 3 – the new treatment challenge. Aliment Pharmacol Ther 2014; 39: 686-698 [PMID: 24612116 DOI: 10.1111/apt.12646]

P- Reviewer: Brillanti S S- Editor: Song XX L- Editor: A E- Editor: Li RF
